🇺🇸 FDA
Pipeline program

Open Label Topical Beremagene Geperpavec (B-VEC)

B-VEC-EX-02

Phase 3 mab completed

Quick answer

Open Label Topical Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa is a Phase 3 program (mab) at Krystal Biotech with 1 ClinicalTrials.gov record(s).

Program details

Company
Krystal Biotech
Indication
Dystrophic Epidermolysis Bullosa
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials